Oxford launches Singula Bio to show cancer need not be fatal
Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers. This patient-centred approach will pioneer immunological, medical, surgical and computational technologies to generate selective therapies that eliminate cancer. The ultimate hope is to achieve long-term, high-quality disease-free survival for cancer patients.
Singula Bio was co-founded by Professors Ahmed Ahmed, the late Enzo Cerundolo and Enda McVeigh from Oxford’s Nuffield Department of Women’s & Reproductive Health. Supported by Oxford University Innovation (OUI), the University’s research commercialisation company, the spin-out has secured generous seed-stage funding from the financial investors, IIU Nominees Ltd.
Profs Ahmed and Cerundolo were motivated and inspired to improve the gruelling experience of cancer treatments of their many patients (and laboratory funding from charities Ovarian Cancer Action and Cancer Research UK).
With an extensive background in cancer medicine, cancer immunology, cell and molecular biology and computational biology, they have been able to design patient-specific cancer cell therapies to harness the power of the patient’s own immune system to fight cancer.